Devatis Inc.
20 drugs in NADAC|20 Generic,0 Brand
Devatis Inc. lists 20 NDCs in the CMS NADAC file (20 generic, 0 brand), at an average NADAC of $5.30 per unit, with a week-over-week move of -2.4% across products that moved. The firm's full portfolio, pricing trend are listed below.
Total Drugs
20
20G / 0B
Avg Price / Unit
$5.3011
$0.25 – $21.41
Avg 7d Change
-2.39%
Across 11 drugs with changes
7d Activity
of 20 total drugs
Portfolio Price Trend
Monthly average NADAC price across all drugs
Keep following this manufacturer
These next-step links connect the manufacturer page to the markets, classes, and trend views most likely to deepen research.
Lead market
Temozolomide market
See the molecule this manufacturer shows up in most often and compare it against competing suppliers.
Lead class
Alkylating Drug therapeutic class
Review the broader class where Devatis Inc. has the strongest current portfolio footprint.
Trend hub
Portfolio trend view
Jump to the trend hub to compare this manufacturer against the rest of the market on weekly price movement.
Guide
NADAC pricing primer
Use the explainer for context on the benchmark this manufacturer is being compared against.
Frequently Asked Questions
How many drugs does Devatis Inc. make?
Devatis Inc. lists 20 NDCs in the CMS NADAC file — 20 generic and 0 brand products.
What is the average price of Devatis Inc. drugs?
The average NADAC across Devatis Inc.'s portfolio is $5.3011 per unit, ranging from $0.2525 to $21.4132.
What types of drugs does Devatis Inc. make?
Devatis Inc. makes drugs across 6 FDA pharmacologic classes. The most common by NDC count are Alkylating Drug (11), Penicillin-class Antibacterial (3), beta Lactamase Inhibitor (3), Calcineurin Inhibitor Immunosuppressant (2), beta2-Adrenergic Agonist (2).
Has Devatis Inc. had any drug recalls?
No FDA enforcement recalls are matched to Devatis Inc. in the openFDA feed.
How has Devatis Inc.'s pricing changed recently?
Over the past 7 days, 3 Devatis Inc. products rose and 8 fell, with a portfolio-wide average change of -2.4%.